Solid lipid nanoparticles of amphotericin B (AmbiOnp): in vitro and in vivo assessment towards safe and effective oral treatment module

Drug Delivery and Translational Research

Volumn 6, Issue 4, 2016, Pages 354-364

  Chaudhari, Manisha B ^a   Desai, Preshita P ^a   Patel, Pratikkumar A ^a   Patravale, Vandana B ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Aggregation state; AmbiOnp; Nephrotoxicity; Oral bioavailability; Solid lipid nanoparticles

Indexed keywords

AMPHOTERICIN B; CREATININE; SOLID LIPID NANOPARTICLE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANDIDA ALBICANS; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PH; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRASOUND; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG STABILITY; KIDNEY; MEDICINAL CHEMISTRY; METABOLISM; MICROBIAL SENSITIVITY TEST; PHARMACOKINETICS; PHARMACOLOGY; SYNTHESIS; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; BIOLOGICAL AVAILABILITY; CANDIDA ALBICANS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; FEMALE; KIDNEY; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; RATS; TISSUE DISTRIBUTION;

EID: 84979034957     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-015-0267-6     Document Type: Article

References (12)

1. Patel PA, Patravale VB. AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. J Biomed Nanotechnol. 2011;7(5):632–9.
2. Wasan KM, Wasan EK, Gershkovich P, Zhu X, Tidwell RR, Werbovetz KA, et al. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis. 2009;200(3):357–60.
3. Barwicz J, Tancrède P. The effect of aggregation state of amphotericin-B on its interactions with cholesterol- or ergosterol-containing phosphatidylcholine monolayers. Chem Phys Lipids. 1997;85(2):145–55.
4. Bolard J, Legrand P, Heitz F, Cybulska B. One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry. 1991;30(23):5707–15.
5. Italia JL, Yahya MM, Singh D, Ravi Kumar MN. Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone. Pharm Res. 2009;26(6):1324–31.
6. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20.
7. Louria DB. Some aspects of the absorption, distribution, and excretion of amphotericin B in man. Antibiotic Med Clin Ther. 1958;5(5):295–301.
8. Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. Amphotericin B formulations and drug targeting. J Pharm Sci. 2008;97(7):2405–25.
9. Gruszecki WI, Gagoś M, Hereć M. Dimers of polyene antibiotic amphotericin B detected by means of fluorescence spectroscopy: molecular organization in solution and in lipid membranes. J Photochem Photobiol B. 2003;69(1):49–57.
10. Tancrède P, Barwicz J, Jutras S, Gruda I. The effect of surfactants on the aggregation state of amphotericin B. Biochim Biophys Acta. 1990;1030(2):289–95.
11. Espada R, Valdespina S, Alfonso C, Rivas G, Ballesteros MP, Torrado JJ. Effect of aggregation state on the toxicity of different amphotericin B preparations. Int J Pharm. 2008;361(1–2):64–9.
12. Duarte M, Giordani RB, De Carli GA, Zuanazzi JA, Macedo AJ, Tasca T. A quantitative resazurin assay to determinate the viability of Trichomonas vaginalis and the cytotoxicity of organic solvents and surfactant agents. Exp Parasitol. 2009;123(2):195–8.